Abstract:
본 발명은 천연물에서 유래된 신규 히스톤 디아세틸라아제(HDAC) 억제제를 유효성분으로 포함하는, 암 예방, 개선, 또는 치료용 조성물에 관한 것으로, 보다 구체적으로, 본 발명은 천연물 유래 신규 비하이드록사메이트(non-hydroxamate)계 HDAC 억제제 화합물인 3,5-di-O-caffeoyl quinic acid methyl ester 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물 및 암 예방 또는 개선용 건강 기능성 식품 조성물에 관한 것이다. 본 발명의 히스톤 디아세틸라아제 억제제는 천연물 유래 화합물로써 부작용이 거의 없고, 항암 효과가 뛰어나므로, 항암 용도로 유용하게 활용될 수 있다.
Abstract:
A novel pyrazolidine compound is provided to inhibit the biological function of a Z-DNA bonding protein by being specifically coupled to the Z-DNA bonding protein, thereby being used as an anti-viral agent. A pharmaceutical composition for controlling activity of a Z-DNA bonding protein comprises a therapeutically effective amount of a pyrazolidine compound represented by a formula(1) or a pharmaceutically acceptable salt and a pharmaceutical carrier or an excipient. In the formula(1), R1 is C6-20 aryl; R2 is C5-20 aryl or C5-20 heterocycle including O or N; each X and Y is independently C or N. A pharmaceutical composition for treating or preventing fox virus or vaccinia virus comprises the compound of the formula(1) or the pharmaceutically acceptable salt thereof and the pharmaceutically acceptable carrier or the excipient.
Abstract:
The present invention relates to penoxazone-, triazine- and pyrazolopyrimidine-based c-myc inhibitor compositions and, more specifically, to a method for manufacturing the same and a pharmaceutical composition for preventing or treating cancer including the same as an active ingredients. The penoxazone-, triazine- and pyrazolopyrimidine-based chemical compounds of the present invention selectively stabilize the G-quadruplex structure of a c-myc promoter, thereby showing inhibiting effects of c-myc expression. This is a development of a new DNA targeting anti-cancer material beyond the limits of the existing DNA binding anti-cancer material, and excellent anti-cancer candidate material deducted the optimization of the chemical compounds of the present invention can be developed as an anticancer medicine for various cancers such as lung cancer, colorectal cancer, breast cancer, bladder cancer and leukemia, therefore is expected to be used in cancer treatment.
Abstract:
A pharmaceutical composition comprising a homopiperazine compound is provided to show excellent activity on inhibiting acute respiratory syndrome and minimize resistance against a drug, thereby being useful as an anti-viral agent. A pharmaceutical composition for inhibiting protein generation induced by -1 frame shift by bonding to an RNA pseudoknot structure specifically existing in SARA(Severe Acute Respiratory Syndrome) coronavirus or for preventing or treating virus comprises a therapeutically effective amount of a homopiperazine compound represented by a formula(1) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier or an excipient. In the formula(1), R is H, C1-6 alkyl, C3-10 aryl, or C3-10 heteroaryl including N or O; X and Y is independently C or N; and Z is O, S or N, provided that X, Y and Z may be substituted with halogen or C1-6 alkyl.